Evidence map›Paper›PMID 33836597›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells.

Hemant Giri, Sumith R Panicker, Xiaofeng Cai, Indranil Biswas, Hartmut Weiler, Alireza R Rezaie

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 83 citations in OpenAlex.

  1. Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Trial
  2. Targeting Oxidative and Immune Dysregulation in Wound Healing via Gold Nanoparticle Conjugate Chitosan.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Review
  4. Article
  5. Thrombin generation profiling in multiple myeloma: a comprehensive evaluation of prothrombotic state.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hemant GiriCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.
Sumith R PanickerCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0001-8550-9436
Xiaofeng CaiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.
Indranil BiswasCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0003-2479-0249
Hartmut WeilerBlood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53226.
Alireza R RezaieCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104; ray-rezaie@omrf.org.ORCID 0000-0002-5302-0553
Oklahoma Medical Research Foundation · USVersiti Blood Center of Wisconsin · US

Funding

Protease Activated Receptor Signaling by Coagulation ProteasesR01HL101917 · NHLBI · SAINT LOUIS UNIVERSITY · PI Lijun Xia · 2010 to 2026
$6.6M
Serpin Regulation of Coagulation ProteasesR01HL062565 · NHLBI · SAINT LOUIS UNIVERSITY · PI REZAIE, ALIREZA R. · 1999 to 2020
$6.2M
Protein C pathway function in hematopoiesisR01HL117132 · NHLBI · VERSITI WISCONSIN, INC. · PI WEILER, HARTMUT KARL-HEINZ · 2014 to 2017
$1.7M
NHLBI NIH HHS R01 HL062565NHLBI NIH HHS R01 HL101917NHLBI NIH HHS R01 HL117132
6 · The paper itself

Abstract

Thrombomodulin (TM) is a thrombin receptor on endothelial cells that is involved in promoting activation of the anticoagulant protein C pathway during blood coagulation. TM also exerts protective anti-inflammatory properties through a poorly understood mechanism. In this study, we investigated the importance of TM signaling to cellular functions by deleting it from endothelial cells by CRISPR-Cas9 technology and analyzed the resultant phenotype of TM-deficient (

Indexed as

Angiopoietin-2AnimalsBlood PlateletsCapillary PermeabilityCell AdhesionEndothelial CellsEndothelium, VascularHumansInflammationLeukocytesLungMiceReceptor, PAR-1ThrombinThrombomodulinvon Willebrand FactorAngiopoietin-2Receptor, PAR-1THBD protein, humanThrombinThrombomodulinvon Willebrand FactorCRISPR-Cas9inflammationPAR1thrombomodulinVWF

Identifiers

PMID33836597
PMCPMC7980409
OpenAlexW3133764846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.